Henri Jasper (via Buck Institute for Research on Aging)
March 16, 2022 06:35 AM EDT
R&D

An Al­tos Labs ri­val? Genen­tech throws its hat in­to buzzy 'cel­lu­lar re­ju­ve­na­tion' field

Paul Schloesser

Associate Editor

Just a few short months af­ter Al­tos Labs made its de­but flush with $3 bil­lion in cash, a fa­mous CEO and a star-stud­ded sci­en­tif­ic team …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times